Clinical Trials Directory

Trials / Unknown

UnknownNCT01372891

Urine Adiponectin Concentration in Prediction of Contrast Induced Nephropathy

Urine Total Adiponectin and Its Isoforms Concentration in Prediction of Percutaneous Coronary Interventions Contrast Induced Nephropathy

Status
Unknown
Phase
Study type
Observational
Enrollment
400 (estimated)
Sponsor
Xijing Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of contrast induced nephropathy (CIN) in the patients undergoing PCI.

Detailed description

Contrast induced nephropathy (CIN) is a severe complication after percutaneous coronary intervention (PCI). CIN is responsible for approximately genic renal insufficiency and is the third cause of hospital-acquired renal failure and the injury of endothelial of renal tubule is responsible for the CIN. However markers reliably identifying CIN in the patients undergoing PCI are rare. Adiponectin is a 30-kDa adipocyte-derived vasoactive peptide closely linked to components of the metabolic syndrome. Recent study demonstrates that the quantification of urinary adiponectin excretion appears to be an independent indicator of vascular damage potentially identifying an increased risk for vascular events. Therefore, the investigators presume that the adiponectin excretion may predict the incidence of the CIN. The present study is to determine the ability of urinary total adiponectin and its isoforms excretion in the prediction of CIN in the patients undergoing PCI.

Conditions

Timeline

Start date
2010-04-01
Primary completion
2013-04-01
Completion
2014-12-01
First posted
2011-06-14
Last updated
2011-11-22

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01372891. Inclusion in this directory is not an endorsement.